Medivation Inc (NASDAQ:MDVN) announced that new data from Company-sponsored and investigator-initiated clinical trials will be presented at the European Society for Medical Oncology (ESMO) …
Pfizer will acquire Medivation for $81.50 per share in cash- an offer unlikely to be bested, says Brean Capital
Today’s biggest news is coming from Pfizer Inc. (NYSE:PFE), which announced its offer to acquire Medivation Inc (NASDAQ:MDVN) in a stock deal worth …
Medivation, Inc. (NASDAQ:MDVN) and Pfizer Inc.
In a research report published Wednesday, Canaccord analyst John Newman reiterated a Buy rating on shares of Medivation Inc (NASDAQ:MDVN) with a price target …
Medivation Inc (NASDAQ:MDVN) reported its financial results for the quarter ended June 30, 2016 and reaffirmed full-year 2016 financial guidance. U.
Analyst Geoff Porges of Leerink Partners discussed Medivation Inc’s (NASDAQ:MDVN) pipeline drug, talazoparib, after listening into a conference call sponsored by the company. On the …
With earning season for Biotech companies approaching, Jefferies’ analysts detailed their thoughts on several mid to large cap biotech companies. The analysts anticipate …
Medivation Inc (NASDAQ:MDVN) announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) recommends that Medivation’s stockholders support the Company’s Board …
Medivation Inc (NASDAQ:MDVN) announced results from a Phase I/II study of pidilizumab, an investigational antibody with immune-mediated anti-tumor effects, that demonstrated potential clinical benefit …